Menu
← Oncology Approval Tracker
FDA DECISION ·
Venclexta combinations
venetoclax + azacitidine, decitabine or low-dose cytarabine · AbbVie
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Newly diagnosed acute myeloid leukemia in adults aged 75 or older or with comorbidities preventing intensive induction chemotherapy, in combination with azacitidine, decitabine or low-dose cytarabine.
LAMPGEN ANALYSIS
Why it matters
Converted an accelerated indication to regular approval with randomized evidence for lower-intensity regimens.
What research teams should watch
Document why intensive induction is unsuitable and build tumor lysis, cytopenia and interaction checks into startup.
PRIMARY RECORDS